124 related articles for article (PubMed ID: 37726528)
1. Proteomic landscape of primary and metastatic brain tumors for heterogeneity discovery.
Yang S; Zhou C; Zhang L; Xiong Y; Zheng Y; Bian L; Liu X
Proteomics Clin Appl; 2024 Mar; 18(2):e2300010. PubMed ID: 37726528
[TBL] [Abstract][Full Text] [Related]
2. Tissue Proteome Analysis of Different Grades of Human Gliomas Provides Major Cues for Glioma Pathogenesis.
Gollapalli K; Ghantasala S; Atak A; Rapole S; Moiyadi A; Epari S; Srivastava S
OMICS; 2017 May; 21(5):275-284. PubMed ID: 28481733
[TBL] [Abstract][Full Text] [Related]
3. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.
Wakimoto H; Tanaka S; Curry WT; Loebel F; Zhao D; Tateishi K; Chen J; Klofas LK; Lelic N; Kim JC; Dias-Santagata D; Ellisen LW; Borger DR; Fendt SM; Vander Heiden MG; Batchelor TT; Iafrate AJ; Cahill DP; Chi AS
Clin Cancer Res; 2014 Jun; 20(11):2898-909. PubMed ID: 24714777
[TBL] [Abstract][Full Text] [Related]
4. Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas.
Salloum R; McConechy MK; Mikael LG; Fuller C; Drissi R; DeWire M; Nikbakht H; De Jay N; Yang X; Boue D; Chow LML; Finlay JL; Gayden T; Karamchandani J; Hummel TR; Olshefski R; Osorio DS; Stevenson C; Kleinman CL; Majewski J; Fouladi M; Jabado N
Acta Neuropathol Commun; 2017 Oct; 5(1):78. PubMed ID: 29084603
[TBL] [Abstract][Full Text] [Related]
5. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.
Pope WB; Prins RM; Albert Thomas M; Nagarajan R; Yen KE; Bittinger MA; Salamon N; Chou AP; Yong WH; Soto H; Wilson N; Driggers E; Jang HG; Su SM; Schenkein DP; Lai A; Cloughesy TF; Kornblum HI; Wu H; Fantin VR; Liau LM
J Neurooncol; 2012 Mar; 107(1):197-205. PubMed ID: 22015945
[TBL] [Abstract][Full Text] [Related]
6. Integrated proteomic analysis of low-grade gliomas reveals contributions of 1p-19q co-deletion to oligodendroglioma.
Wong D; Lee TH; Lum A; Tao VL; Yip S
Acta Neuropathol Commun; 2022 May; 10(1):70. PubMed ID: 35526077
[TBL] [Abstract][Full Text] [Related]
7. Defining Protein Pattern Differences Among Molecular Subtypes of Diffuse Gliomas Using Mass Spectrometry.
Djuric U; Lam KHB; Kao J; Batruch I; Jevtic S; Papaioannou MD; Diamandis P
Mol Cell Proteomics; 2019 Oct; 18(10):2029-2043. PubMed ID: 31353322
[TBL] [Abstract][Full Text] [Related]
8. Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas.
Schreck KC; Ranjan S; Skorupan N; Bettegowda C; Eberhart CG; Ames HM; Holdhoff M
J Neurooncol; 2019 May; 143(1):87-93. PubMed ID: 30864101
[TBL] [Abstract][Full Text] [Related]
9. Proteomics separates adult-type diffuse high-grade gliomas in metabolic subgroups independent of 1p/19q codeletion and across IDH mutational status.
Bader JM; Deigendesch N; Misch M; Mann M; Koch A; Meissner F
Cell Rep Med; 2023 Jan; 4(1):100877. PubMed ID: 36584682
[TBL] [Abstract][Full Text] [Related]
10. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.
Weller M; Weber RG; Willscher E; Riehmer V; Hentschel B; Kreuz M; Felsberg J; Beyer U; Löffler-Wirth H; Kaulich K; Steinbach JP; Hartmann C; Gramatzki D; Schramm J; Westphal M; Schackert G; Simon M; Martens T; Boström J; Hagel C; Sabel M; Krex D; Tonn JC; Wick W; Noell S; Schlegel U; Radlwimmer B; Pietsch T; Loeffler M; von Deimling A; Binder H; Reifenberger G
Acta Neuropathol; 2015 May; 129(5):679-93. PubMed ID: 25783747
[TBL] [Abstract][Full Text] [Related]
11. Multiscale, multimodal analysis of tumor heterogeneity in IDH1 mutant vs wild-type diffuse gliomas.
Berens ME; Sood A; Barnholtz-Sloan JS; Graf JF; Cho S; Kim S; Kiefer J; Byron SA; Halperin RF; Nasser S; Adkins J; Cuyugan L; Devine K; Ostrom Q; Couce M; Wolansky L; McDonough E; Schyberg S; Dinn S; Sloan AE; Prados M; Phillips JJ; Nelson SJ; Liang WS; Al-Kofahi Y; Rusu M; Zavodszky MI; Ginty F
PLoS One; 2019; 14(12):e0219724. PubMed ID: 31881020
[TBL] [Abstract][Full Text] [Related]
12. Proteomic analysis of brain metastatic lung adenocarcinoma reveals intertumoral heterogeneity and specific alterations associated with the timing of brain metastases.
Woldmar N; Schwendenwein A; Kuras M; Szeitz B; Boettiger K; Tisza A; László V; Reiniger L; Bagó AG; Szállási Z; Moldvay J; Szász AM; Malm J; Horvatovich P; Pizzatti L; Domont GB; Rényi-Vámos F; Hoetzenecker K; Hoda MA; Marko-Varga G; Schelch K; Megyesfalvi Z; Rezeli M; Döme B
ESMO Open; 2023 Feb; 8(1):100741. PubMed ID: 36527824
[TBL] [Abstract][Full Text] [Related]
13. cMYC expression in infiltrating gliomas: associations with IDH1 mutations, clinicopathologic features and outcome.
Odia Y; Orr BA; Bell WR; Eberhart CG; Rodriguez FJ
J Neurooncol; 2013 Nov; 115(2):249-59. PubMed ID: 23934175
[TBL] [Abstract][Full Text] [Related]
14. ZEB1 expression is increased in IDH1-mutant lower-grade gliomas.
Nesvick CL; Zhang C; Edwards NA; Montgomery BK; Lee M; Yang C; Wang H; Zhu D; Heiss JD; Merrill MJ; Ray-Chaudhury A; Zhuang Z
J Neurooncol; 2016 Oct; 130(1):111-122. PubMed ID: 27568035
[TBL] [Abstract][Full Text] [Related]
15. IDH1 status is significantly different between high-grade thalamic and superficial gliomas.
Zuo M; Li M; Chen N; Yu T; Kong B; Liang R; Wang X; Mao Q; Liu Y
Cancer Biomark; 2017 Aug; 20(2):183-189. PubMed ID: 28869450
[TBL] [Abstract][Full Text] [Related]
16. Proteomics-based analysis of invasion-related proteins in malignant gliomas.
Maruo T; Ichikawa T; Kanzaki H; Inoue S; Kurozumi K; Onishi M; Yoshida K; Kambara H; Ouchida M; Shimizu K; Tamaru S; Chiocca EA; Date I
Neuropathology; 2013 Jun; 33(3):264-75. PubMed ID: 23116197
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic algorithm for pathological evaluation of gliomas in a resource-constrained setting.
Jain S; Gupta P; Shankar KB; Singh R; Siraj F
J Cancer Res Ther; 2023; 19(3):562-566. PubMed ID: 37470575
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral Susceptibility Signals Reflect Biomarker Status in Gliomas.
Kong LW; Chen J; Zhao H; Yao K; Fang SY; Wang Z; Wang YY; Li SW
Sci Rep; 2019 Nov; 9(1):17080. PubMed ID: 31745161
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of the TWEAK receptor Fn14 in IDH1 wild-type and mutant gliomas.
Hersh DS; Peng S; Dancy JG; Galisteo R; Eschbacher JM; Castellani RJ; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
J Neurooncol; 2018 Jun; 138(2):241-250. PubMed ID: 29453678
[TBL] [Abstract][Full Text] [Related]
20. Altered metabolic landscape in IDH-mutant gliomas affects phospholipid, energy, and oxidative stress pathways.
Fack F; Tardito S; Hochart G; Oudin A; Zheng L; Fritah S; Golebiewska A; Nazarov PV; Bernard A; Hau AC; Keunen O; Leenders W; Lund-Johansen M; Stauber J; Gottlieb E; Bjerkvig R; Niclou SP
EMBO Mol Med; 2017 Dec; 9(12):1681-1695. PubMed ID: 29054837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
